Goldman Sachs Reinstates Buy on Neurocrine Biosciences, Announces $213 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 72.3%

Neg 0% Neu 72.3% Pos 0%

Goldman Sachs analyst Corinne Johnson reinstates Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and announces $213 price target.